Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan Switch in CTD-PAH
NCT02885012Phase 4Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Jun 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Medical University of South Carolina. Started Jun 2016; status: terminated.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02885012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885012.